Surface Oncology Inc

Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Surface Oncology was created to advance next-generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno-biology. Together with world-leading scientific founders, the Company is advancing multiple preclinical programs that target novel mechanisms shown to play vital roles in tumor immune evasion.

CAMBRIDGE, Mass., May  15, 2020  (GLOBE NEWSWIRE) --  Surface Oncology  (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced five scientific posters sharing updated preclinical data at the American Association for Cancer Research (AACR) 2020 Annual Meeting, to be held virtually on June 22-24.

Surface Oncology to Present Preclinical Data for Multiple Product Programs at the American Association for Cancer Research Annual Meeting

CAMBRIDGE, Mass., May  12, 2020  (GLOBE NEWSWIRE) --  Surface Oncology  (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the first quarter 2020, as well as anticipated corporate milestones for 2020.

Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2020

Surface Oncology Inc (SURF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Surface Oncology Inc (SURF) to Report Q1 Results: Wall Street Expects Earnings Growth

CAMBRIDGE, Mass., April  23, 2020  (GLOBE NEWSWIRE) --  Surface Oncology  (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has initiated a Phase 1 clinical trial of its first-in-class antibody SRF388, which targets the immunosuppressive cytokine IL-27.

Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Antibody SRF388

CAMBRIDGE, Mass., March  17, 2020  (GLOBE NEWSWIRE) --  Surface Oncology  (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has initiated a Phase 1/1b clinical trial of its antibody candidate SRF617, which targets the immunosuppressive protein CD39.

Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Candidate SRF617

Is  (SURF) Outperforming Other Medical Stocks This Year?

Is Surface Oncology (SURF) Outperforming Other Medical Stocks This Year?

Is Surface Oncology (SURF) Stock Outpacing Its Medical Peers This Year?

As of late, it has definitely been a great time to be an investor Surface Oncology, Inc. (SURF).

Surface Oncology, Inc. (SURF) Shares March Higher, Can It Continue?

Company focuses efforts and resources on advancing SRF617 and SRF388; Implements strategic restructuring

Surface Oncology Announces FDA Clearance of SRF617 and SRF388 INDs to Initiate Phase 1 Clinical Trials

CAMBRIDGE, Mass., Nov.  25, 2019  (GLOBE NEWSWIRE) --  Surface Oncology  (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced it has secured a debt financing facility for up to $25 million from K2 HealthVentures, a healthcare-focused specialty finance company. Surface received a first tranche of $7.5 million upon closing. Two subsequent tranches totaling $17.5 million will become available to the Company upon the achievement of certain milestones.

Surface Oncology Announces $25 Million Debt Financing from K2 HealthVentures

Details clinical plans for phase 1/1b clinical studies of SRF617 and SRF388 in patients with advanced solid tumors

Surface Oncology Announces Filing of IND for CD39 Targeted Antibody Candidate, SRF617, at Inaugural R&D Day

Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of -5.17% and -86.24%, respectively, for the quarter ended September 2019.

Surface Oncology, Inc. (SURF) Reports Q3 Loss, Lags Revenue Estimates

Company to provide additional updates at its inaugural R&D day on November 18th in New York Company to provide additional updates at its inaugural R&D day on November 18th in New York

Surface Oncology Presents Updates at the Society for Immunotherapy of Cancer’s Annual Meeting

CAMBRIDGE, Mass., Sept.  03, 2019  (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, and Vito Palombella, Ph.D., chief scientific officer, will participate in a fireside chat at the Baird 2019 Global Healthcare Conference. The presentation will take place on Wednesday, September 4th, 2019 at 1:25PM ET at the Intercontinental New York Barclay Hotel, in New York, NY.

Surface Oncology to Present at the Baird 2019 Global Healthcare Conference

Chief medical officer at Parker Institute for Cancer Immunotherapy to add immuno-oncology clinical development & industry leadership experience Chief medical officer at Parker Institute for Cancer Immunotherapy to add immuno-oncology clinical development & industry leadership experience

Ramy Ibrahim, M.D. to Join Surface Oncology Board of Directors

Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of -3.23% and -94.28%, respectively, for the quarter ended June 2019.

Surface Oncology, Inc. (SURF) Reports Q2 Loss, Lags Revenue Estimates

Surface Oncology, Inc. (SURF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Will Surface Oncology, Inc. (SURF) Report Negative Q2 Earnings?

Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of 65.91% and 477.36%, respectively, for the quarter ended March 2019.

News for Surface Oncology Inc Stock (SURF)